The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Machine learning (ML)-based quantification of tumor-infiltrating lymphocytes (TIL) and clinical outcomes of patients with melanoma treated with immune-checkpoint inhibitors (ICI).
 
Elio Adib
Employment - Amgen (I)
 
Mehrdad Rakaee
No Relationships to Disclose
 
Amin Nassar
No Relationships to Disclose
 
Elias Bou Farhat
No Relationships to Disclose
 
F. Stephen Hodi
Employment - Dana-Farber Cancer Institute
Leadership - Bicara Therapeutics
Stock and Other Ownership Interests - Apricity Health; Bicara Therapeutics; Pionyr; Torque
Consulting or Advisory Role - AstraZeneca; Bioentre; Bristol-Myers Squibb; Catalym; Checkpoint THerapeutics; Compass Therapeutics; Corner Therapeutics; Curis; Genentech/Roche; Gossamer Bio; Immunocore; Iovance Biotherapeutics; Kairos Therapeutics; Merck Sharp & Dohme; Novartis; Rheos Medicines; Surface Oncology; Zumutor Biologics
Research Funding - bristol-myers squibb (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst); novartis (Inst)
Patents, Royalties, Other Intellectual Property - Angiopoietin-2 Biomarkers Predictive of Anti-immune checkpoint response (Inst); Compositions and Methods for Identification, Assessment, Prevention, and Treatment of Melanoma using PD-L1 Isoforms; Methods of Using Pembrolizumab and Trebananib (Inst); patent pending as per institutional policy; patent pending royalties received on MICA related disorders application to institution per institutional IP policy
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis
Other Relationship - Bristol-Myers Squibb; Genentech/Roche
 
David J. Kwiatkowski
Consulting or Advisory Role - AADI; Genentech/Roche
Research Funding - AADi; Genentech/Roche; Revolution Medicines